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Interleukin-19, 20, and 24 are new members of the IL-10
family binding and signaling through the IL-20R1/IL-
20R2 heterodimer, while IL-20 and 24 also bind to the
IL-20R2/IL-22R1 heterodimer. Using in situ hybridiza-
tion we have studied mRNA expression of IL-19, 20,
and 24 and their related receptor chains in skin from
psoriatic patients before and during short-term treat-
ment with either oral cyclosporine A or topical calcipo-
triol. In untreated lesions IL-19 and IL-20 mRNA was
expressed focally in epidermis above the dermal papil-
lae, whereas IL-24 was expressed in mononuclear cells
in the dermal in¢ltrate. The expression of IL-19 and 20
mRNAwas con¢ned to the basal and suprabasal kerati-
nocytes. No expression of IL-19 and 20 mRNA could be
detected in uninvolved psoriatic skin. Treatment with
cyclosporine A and calcipotriol resulted in disappear-
ance of the IL-19 and 20 mRNA. Expression of mRNA
for the receptor chains IL-20R1 and IL-20R2 was found
throughout the psoriatic epidermal layer, whereas IL-
22R1 mRNAwas predominantly expressed in the super-
¢cial part of the psoriatic epidermis. These ¢ndings
show that IL-19 and IL-20 are synthesized by a distinct
population of keratinocytes. It remains to be clari¢ed
whether IL-19 and IL-20 are implicated in the pathogen-
esis of psoriasis. Key words: in£ammation/interleukin-19/
interleukin-20/interleukin-24/keratinocytes/psoriatic plaque.
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P
soriasis is characterized by scaly, red cutaneous plaques
that contain in£ammatory in¢ltrates and epidermal
hyperproliferation. Evidence that the disorder has an
immune cause comes from the observation that treat-
ment with cyclosporine dramatically improved psoria-
sis (Ellis et al, 1991). A particular role of T cells in the psoriatic
pathogenesis has been demonstrated by several lines of evidence.
Injection of CD4þ T cells induced plaques in hitherto unin-
volved skin showing that T cells may be responsible for the phe-
notypic conversion of symptom-less skin in psoriatic patients
(Nickolo¡ and Wrone-Smith, 1999). Furthermore, psoriasis is
attenuated after treatment with suppressors of T cell mediated
immune responses such as interleukin (IL)-10 (Reich et al, 2001;
Friedrich et al, 2002), IL-11 (Trepicchio et al, 1999), and tumor ne-
crosis factor (TNF)-a (Chaudhari et al, 2001). A number of cyto-
kines present in psoriatic lesions are believed to be important in
the activation of epidermal keratinocytes and the in¢ltrating leu-
kocytes (van de Kerkhof, 1999).
IL-19, IL-20, and IL-24 are three recently described members
of the IL-10 cytokine family (Blumberg et al, 2001). All three in-
terleukins bind and signal through the IL-20R1/IL-20R2 hetero-
dimer, whereas IL-20 and IL-24 are also ligands for the receptor
complex composed of IL-20R2 and IL-22R1 (Dumoutier et al,
2001; Fickenscher et al, 2002). These three receptor subunits are
all expressed in the epidermal compartment of the skin (Blum-
berg et al, 2001; Novak et al, 2002).
Transgenic mice that overexpress IL-20 cause neonatal lethality
with skin abnormalities, including a thickened epidermis, hyper-
keratosis, and a compact stratum corneum, indicating that IL-20
plays a part in epidermal function by regulating keratinocyte pro-
liferation and di¡erentiation. In vitro, IL-20 was capable of indu-
cing signal transduction in a keratinocyte cell line. Furthermore,
it was demonstrated that both the receptor chains IL-20R1 and
IL-20R2 were upregulated in human psoriatic skin compared
with normal skin. Based on these data it was suggested that
IL-20 and its receptor complex play a pathogenic role in psoriasis
(Blumberg et al, 2001).
In vitro, IL-19 is capable of induction of IL-6 and TNF-a ex-
pression in monocytes, resulting in TNF-a-mediated apoptosis
(Liao et al, 2002). Otherwise, little is known about the biologic
function and gene regulation of IL-19. IL-24, also known as
MDA-7, was originally identi¢ed as a gene induced during term-
inal di¡erentiation of certain melanoma cells ( Jiang et al, 1995).
To assess the potential role of these cytokines in psoriasis, we
have identi¢ed the cellular origin of mRNA for IL-19, IL-20, and
IL-24 and their related receptor subunits in psoriatic plaques. In
addition, we have determined the e¡ect on IL-19 and IL-20
mRNA expression of short-term treatment with either cyclosporine
A or the vitamin D3 analog calcipotriol, whereas cyclosporine
A improves psoriasis primarily by suppressing T lymphocytes,
vitamin D3 analogs act predominantly on keratinocytes.
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MATERIALS AND METHODS
Patients, treatment regimens, and clinical score The study included
20 adult patients with chronic plaque type psoriasis (Table I). Patients
included had not received topical anti-psoriatic therapy in the previous 2
wk or systemic therapy in the previous 4 wk. It was an open study
approved by the local Ethics Committee. All patients gave written
consent before participating in the study.
Based on the global assessment of the disease severity patients with mild
to moderate disease were treated with calcipotriol ointment 0.5% twice
daily (n¼10), and patients with moderate to severe disease with oral
cyclosporine A 4 mg per kg per day divided in two daily doses (n¼10)
(Table I). Treatment was given for 4 wk. The disease activity of the target
lesions was assessed at weeks 0, day 14 and 28 using the Total Sign Score
(TSS, also known as topical Psoriasis Area and Severity Index or ToPASI)
de¢ned as the sum of erythema, thickness, and scaliness. Erythema,
thickness, and scaliness was graded on a scale from 0 to 4 (0, absent; 4,
severe). The TSS could range from 0 to 12.
Biopsies and histopathologic score Before treatment (day 0), three target
lesions with identical TSS were identi¢ed in each patient. Sequential punch
biopsies (6 mm) were taken from the three di¡erent target lesions before
treatment (day 0) and after treatment for 14 or 28 d. The biopsy was
obtained from the central part of the chronic plaque. A skin biopsy from
uninvolved skin was also obtained at day 0. All biopsies were ¢xed for 12 to
16 h in 4% paraformaldehyde and embedded in para⁄n wax.
A histopathologic score of the biopsies was assessed on hematoxylin^eosin-
stained sections as the degree of parakeratosis, psoriasiform papillary pattern,
vessel density and dilatation in the papillae, lymphocyte in¢ltration around
the super¢cial plexes of vessels, and granulocyte in¢ltration in stratum
corneum. The histopathologic score for each of the ¢ve patterns was graded
on a scale from 1 to 4 (1, absent; 4, severe). The histopathologic score could
range from 5 to 20.
Reverse transcription-polymerase chain reaction and probe
preparation cDNA fragments of human IL-19 (48^578 bp, accession
no. AF192498), IL-20 (45^575 bp, accession no. AF224266), IL-24 (275^895
bp, accession no. U16261), IL-20R1 (804^1187 bp, accession no. AF184971),
IL-20R2 (509^914 bp, accession no. AR252504), and IL-22R1 (125^543 bp,
accession no. AF286095) were generated by reverse transcription^
polymerase chain reaction and cloned in pBlueScript (Stratagene, La Jolla,
California) or pCR-bluntII-TOPO (Invitrogen, Frederick, Maryland) vectors.
These plasmids were used for generation of 35S-uridine triphosphate-
labeled probes by in vitro transcription. Anti-sense or sense probes were
generated with either SP6, T3, or T7 polymerase. All probe preparations
were adjusted to 2  106 cpm per mL. Probes were stored at201C until use.
In situ hybridization In situ hybridization was performed on para⁄n
sections that were heated to 601C for 30 min, depara⁄nized in xylene,
and rehydrated. The slides were acid-treated in 0.2 mol per liter HCl,
treated with proteinase K (5 mg per mL), and subsequently ¢xed in 4%
paraformaldehyde, followed by dehydration before the 35S-uridine
triphosphate-labeled anti-sense or sense probes were added. The sections
were then incubated overnight at 471C in a hybridization solution
containing radiolabeled RNA probe (80 pg per mL) in a solution of 50%
deionized formamide, 10% dextran sulfate, tRNA (1 mg per mL), Ficoll
400 (0.02% wt/vol), 0.02% polyvinylpyrrolidone (wt/vol), 0.2% bovine
serum albumin fraction V (wt/vol), 10 mmol per liter dithiothreitol,
0.3 mol per liter NaCl, 0.5 mmol per liter ethylenediamine tetraacetic acid,
10 mmol per liter Tris^Cl, and 10 mmol per liter sodium phosphate (pH
6.8). After hybridization, slides were washed at 57 and 621C. The sections
were then treated with RNase A (20 mg per mL), dehydrated, and air-dried.
Autoradiographic ¢lm and subsequent emulsion was applied. The sections
were developed after 2 to 3 wk of exposure and stained with hematoxylin^
eosin.
The level of expression of IL-19 and IL-20 mRNA in each biopsy
(n¼ 80) was assessed semiquantitatively. The number of epidermal foci at
the top of papillae with expression of IL-19 and IL-20 mRNAwas counted
in one in situ hybridized section from all patients included in the study.The
sections for quantitation were selected from the middle of the biopsies
(corresponding to an epidermal width of 6 mm). The analysis was
performed on uninvolved skin and psoriatic plaques before (day 0), and
after 14 d or 28 d of treatment with either cyclosporine A or calcipotriol.
The identity of the sections was blinded to the observer.
Immunohistochemistry Two micrometer para⁄n sections were cut,
mounted on ChemMate slides (DAKO, Dakocytomation, Glostrup,
Denmark), and dried 1 h at 601C. The sections were depara⁄nized and
rehydrated. Antigen unmasking was performed by microwave heating in
closed container Tris^EGTA (pH 9.0) for 25 min, followed by cooling in
Tris-bu¡ered saline (TBS; 50 mM Tris, 150 mM NaCl, pH 7.6).
Incubation with the primary antibody was done in DAKO Chemmate
Antibody Diluent (S2022, DAKO) for 60 min followed by rinsing in
TBS (3  3 min). Endogenous peroxidase blocking was done by
incubation in methanol and H2O2 for 12 min. The primary antibody was
detected by incubation for 30 min with Horseradish Peroxidase Envision
polymer (K 4001, DAKO) followed by rinsing in TBS for 3  3 min, and
visualized with the chromogen diaminobenzidine tetrahydrochloride for
10 min and rinsing in TBS for 2 min. The reaction was enhanced by
incubation with a CuSO4 (C-7631, Sigma, St Louis, Missouri) solution
for 5 min. Finally, the sections were counterstained with hematoxylin and
mounted with Aqutex (64912^50, Kebo-Laboratory,WWR International,
Albertslund, Denmark). All immunohistochemical stains were performed
using an automated immunostainer (Techmate 500, DAKO). Positive
controls were added for each stain.
The following mouse monoclonal anti-human IgG were used as
primary antibodies: CD1a, Langerhans cells (dilution 1:40, NCL-CD1a-
235); CD3, T lymphocytes (dilution 1:50, NCL-CD3-PS1); CD4, helper/
inducer T lymphocytes (dilution 1:50, NCL-CD4^1F6) from NovoCastra
Laboratories, Newcastle-Upon-Tyne, UK; CD68, macrophage/monocytes
(dilution 1:200, M0876); CD8, suppressor/cytotoxic T lymphocytes
(dilution 1:100, M7103); CD31, endothelial cells (dilution 1:50, M0823);
Melan A, melanocytes (dilution 1:50, M7196); and MiB 1, Ki-67 antigen,
proliferation marker (dilution 1:100, M7240) from DAKO.
RESULTS
Focal epidermal expression of IL-19 and IL-20 mRNA in
psoriatic plaques The expression of mRNA for IL-19, IL-20,
and IL-24 and their related receptors was analyzed by in situ
hybridization in biopsies from the center of lesions or from
uninvolved skin in psoriatic patients (n¼ 20). In psoriatic lesions
both IL-19 (Fig 1a^c) and IL-20 (Fig 1d^f) mRNA were
exclusively expressed in foci of keratinocytes located at the top
of the dermal papillae. Based on an evaluation of one and in
some cases three hybridized sections from each patient, IL-19
mRNAwas detected in 16 of 20 patients and IL-20 mRNAwas
detected in 17 of 20 patients. Both IL-19 and IL-20 mRNA
expression could be found in either a single focus or in several
foci of basal and suprabasal keratinocytes in the suprapapillary
epidermis. By comparison of adjacent skin sections the overall
IL-19 mRNA expression was stronger than that of IL-20, and
the number of IL-19 positive foci in each biopsy was higher
compared with that of IL-20 mRNA. In most cases the foci
with IL-20 expression were also positive for IL-19 mRNA;
however, in a few cases strong IL-20 mRNA expression could
be detected in foci that were completely devoid of IL-19
mRNA. In one of the patients with undetectable expression
of both IL-19 and IL-20 mRNA the lesion was characterized
by only slightly increased epidermal thickness. Virtually no
expression of IL-19 and IL-20 mRNA was detected in
uninvolved psoriatic skin (Fig 2).
The distinct localization of IL-19 and IL-20 mRNA at the top
of the papillae indicate that the keratinocyte is a source of
mRNA in the psoriatic lesions. To unravel whether other cells
than keratinocytes express IL-19 and IL-20 mRNAwe compared
neighboring sections immunostained with markers for mono-
cyte/macrophages (CD68), endothelial cells (CD31), melanocytes
(Melan A), dendritic Langerhans cells (CD1a), andT lymphocytes
(CD3, CD4, and CD8), and sections hybridized for either IL-19
Table I. Demographic and clinical data before treatment
Calcipotriol Cyclosporine A
(n¼10) (n¼10)
Female/male 2/8 1/9
Age, mean 54 56
TSS, mean 8.7 (7^10) 9.4 (8^11)
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or IL-20 mRNA. This analysis excluded monocytes/macro-
phages, endothelial cells, melanocytes, dendritic Langerhans
cells, or lymphocytes as sources of IL-20 mRNA (Fig 3) and
IL-19 mRNA (data not shown). The absence of immuno-
staining with the proliferation marker MiB 1 (Ki-67 antigen)
showed that the foci of IL-19 (data not shown) and IL-20
(Fig 3i2 and j) expressing keratinocytes were not proliferating.
Expression of IL-24 mRNA in mononuclear in£ammatory
cells in papillae and dermis In psoriatic lesions (n¼ 3) IL-24
mRNA was expressed in single, scattered mononuclear cells
located in the papillae and in the dense in£ammatory areas in
the subpapillary dermis (Fig 1g^i). No expression of IL-24
mRNA could be detected in uninvolved psoriatic skin.
Expression of IL-20R1, IL-20R2, and IL-22R1 in psoriatic
plaques Expression of mRNA for the receptor chains IL-20R1
and IL-20R2 was found throughout the psoriatic epidermis.
IL-20R1 mRNA was predominantly expressed above the basal
layer of keratinocytes (Fig 4a,b), whereas IL-20R2 mRNA was
distributed evenly in all layers of epidermis (Fig 4c,d). IL-22R1
mRNAwas di¡erentially expressed in the most super¢cial part of
the psoriatic epidermis just beneath stratum corneum (Fig 4e,f).
Expression of mRNA for the three receptor chains could not be
detected in any cells located in the dermal compartment.
A similar, although weaker, expression pattern of the three
receptor chains was detected in uninvolved psoriatic skin (data
not shown).
IL-19 and IL-20 mRNA expression disappears following
short-term treatment with cyclosporine A or calcipo-
triol The expression of mRNA for IL-19 and IL-20 and their
related receptors was analyzed by in situ hybridization in biopsies
from psoriatic plaques before and after short-term treatment with
either oral cyclosporine A in patients with medium to severe
psoriasis (n¼10) or topical calcipotriol in patients with mild to
moderate psoriasis (n¼10). In situ hybridization was performed
on sections of biopsies taken from target lesions at 0, 14, or 28 d
after initiation of treatment. Treatment with both cyclosporine A
(Fig 5) and calcipotriol (data not shown) resulted in
disappearance of the focal expression of IL-19 and IL-20
mRNA in keratinocytes at the top of dermal papillae. In the
cyclosporine A-treated patients we found a focal expression of
IL-19 in six of 10 patients and of IL-20 mRNA in nine of 10
patients. After treatment with cyclosporine A for 2 wk mRNA
was only seen in one and two of 10 patients, respectively. After 4
wk of treatment IL-19 mRNA could no longer be detected in
any patient and IL-20 mRNA could only be detected in one
patient (Fig 6A,B). In the calcipotriol-treated patients IL-19 and
IL-20 mRNA expression did not decrease as rapidly as in the
cyclosporine A group. After 4 wk of treatment, however, both
IL-19 and IL-20 mRNA expressions had virtually disappeared
Figure1. Expression of IL-19, IL-20, and IL-24 mRNA in psoriatic
plaques. In situ hybridization with 35S-labeled RNA probes for IL-19
mRNA (a^c), IL-20 mRNA (d^f ), and IL-24 mRNA (g^i) in sections of
an untreated psoriatic plaque (day 0). (a,d,g) Bright¢eld (hematoxylin^eosin
stained) micrographs, and (b,e,h) dark¢eld micrographs of the same areas.
(c,f,i) Magni¢cations of the boxed areas in (b,e,h), respectively. Arrows in
(a^f ) show the expression of IL-19 and IL-20 mRNA in suprapapillary foci
of keratinocytes. Arrowheads in (i) show the expression of IL-24 mRNA
in mononuclear in£ammatory cells in the dermal compartment. Bars¼
100 mm.
Figure 2. In situ hybridization for IL-19 and IL-20 mRNA in unin-
volved psoriatic skin. Dark¢eld micrographs of in situ hybridization
IL-19 mRNA (a) and IL-20 mRNA (b) in sections of uninvolved skin
from a patient with psoriasis vulgaris. Epidermal layer (). Bars¼100 mm.
Figure 3. IL-20 mRNA expression in the suprapapillary epidermis
in psoriatic plaques.Ten serial sections (a^j) of an untreated psoriatic pla-
que (day 0). In situ hybridization for IL-20 mRNA (a1-a2, d, g, i1-i2). The
micrographs in a1-a2 and i1-i2 are bright¢eld/dark¢eld pairs of the same
section. Every other section are immunostained for monocytes/macro-
phages with CD68 (b), for Langerhans cells with CD1a (c), for melanocytes
with Melan A (e), for lymphocytes with CD3 ( f ), for endothelial cells with
CD31 (h) and for proliferating cells with MiB 1 ( j).The arrows indicate the
top of the same papilla with suprapapillary epidermal IL-20 mRNA ex-
pression in all panels. Bars¼100 mm.
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(Fig 6C,D). Treatment with cyclosporine A and calcipotriol
resulted in improvements of both the clinical score (TSS) and a
histopathologic score. Disappearance of IL-19 and IL-20 mRNA
expressions correlated with the changes of the clinical and
histopathologic scores (Fig 7). Expression levels of mRNA for
the three receptor chains were not a¡ected by either cyclo-
sporine A or calcipotriol treatment.
DISCUSSION
In contrast to uninvolved psoriatic skin the cytokines IL-19, IL-
20, and IL-24 were expressed in involved psoriatic skin. IL-19
and IL-20 mRNAwere selectively expressed in epidermis in foci
of basal and suprabasal keratinocytes located within the suprapa-
pillary epidermis. Using immunohistochemical markers the mes-
sage for IL-19 and IL-20 was absent in monocytes/macrophages,
endothelial cells, melanocytes, dendritic Langerhans cells, and T
lymphocytes. Because chronic plaque lesions were studied, it is
unknownwhether IL-19 and/or IL-20 play a part in the induction
of the disease.
This is one of the ¢rst reports to identify keratinocytes as the
source of IL-19 and IL-20 in psoriatic skin. No de¢nitive func-
tions have until now been ascribed to IL-19 or IL-20. In vitro data
have suggested that both IL-19 and IL-20 act as proin£ammatory
cytokines or modulators of the in£ammatory response (Kotenko,
2002). IL-20 mRNA can be induced in lipopolysaccharide-
stimulated monocytes (Gruenberg et al, 2001), and IL-19 can induce
IL-6 and TNF-a production and apoptosis in monocytes (Liao
et al, 2002); however, we have not been able to detect IL-19 or
IL-20 mRNA expression in monocytes/macrophages or in other
in£ammatory cells in¢ltrating the psoriatic lesions.
We found IL-24 mRNA to be expressed in single, scattered
in£ammatory cells in¢ltrating the dermis in the psoriatic plaques.
Our ¢nding of IL-24 mRNA expression in mononuclear cells in
psoriatic lesions is in line with the previously reported expression
of IL-24 in mononuclear cells, speci¢cally monocytes (Wang
et al, 2002). IL-24 also known as melanoma di¡erentiation asso-
ciated (MDA-7) gene has tumor inhibitory and apoptosis-indu-
cing potential (Gruenberg et al, 2001; Huang et al, 2001; Caudell
et al, 2002;Wang et al, 2002). The mouse IL-24 ortholog, FISP, has
been reported to be secreted by T helper (Th)2 lymphocytes
(Schaefer et al, 2001) and the rat ortholog, Mob-5 or c49a, has
been found in ¢broblast-like cells during skin wound healing
and in ras-transformed ¢broblasts (Soo et al, 1999; Wang et al,
2002). Based on morphology, however, we did not detect any ex-
pression of IL-24 mRNA in melanocytes, ¢broblasts, or lym-
phocytes in the psoriatic lesions.
We found that the message for IL-20R1 and IL-20R2 were ex-
pressed virtually throughout the epidermis of involved psoriatic
skin, whereas we were not able to detect expression of IL-20R1
or IL-20R2 in endothelial cells or leukocytes in dermis. IL-22R1
mRNA has previously been described in normal skin (Novak
et al, 2002) and we found that it was predominantly expressed in
the most super¢cial part of the involved psoriatic epidermis just
Figure 4. Expression of IL-20Ra, IL-20Rb, and IL-22Ra mRNA in
psoriatic plaques. In situ hybridization for IL-20Ra (a,b), IL-20Rb (c,d )
and IL-22Ra (e,f ) mRNA in sections of an untreated psoriatic plaque (day
0). (a,c,e) Bright¢eld micrographs, and (b,d,f ) dark¢eld micrographs of the
same areas. Expression of IL-22Ra mRNA in stratum spinosum (arrows)
just beneath the corni¢ed layer. Bars¼100 mm.
Figure 5. IL-19 and IL-20 mRNA expression in psoriatic plaques
following treatment with either cyclosporine A or calcipotriol.
Dark¢eld micrographs of in situ hybridization for IL-19 mRNA (a^c) and
IL-20 mRNA (d^f ) in sections from psoriatic plaques untreated (a,d ), after
treatment for 14 d (b,e) and 28 d (c,f ). Expression of IL-19 (arrows in a and b)
and IL-20 mRNA (arrows in d and e) in suprapapillary keratinocytes.
Bars¼100 mm.
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beneath the stratum corneum. Because we could only detect a
weak expression of all three messengers in uninvolved psoriatic
skin, these data are in line with the previously reported upregula-
tion of mRNA for both IL-20R1 and IL-20R2 in the epidermal
layer of psoriatic skin (Blumberg et al, 2001).
Blumberg et al (2001) have demonstrated that overexpression of
IL-20 under di¡erent promoters in transgenic mice caused neo-
natal lethality with skin abnormalities, including a thickened epi-
dermis, hyperkeratosis, and a compact stratum corneum. These
data indicate that IL-20, directly or indirectly, plays a part in epi-
dermal function by dysregulation of keratinocyte proliferation
and di¡erentiation. Our demonstration of a distinct epidermal
expression of IL-20 in psoriatic lesions supports this notion.
IL-19 transgenic mice have been reported to have no overt skin
phenotype (Novak et al, 2002), and no function has so far been
assigned to IL-19. Our demonstration, however, of a focal supra-
papillary epidermal expression of IL-19 in psoriatic lesions, and
the previously described ¢nding that IL-19 is capable of inducing
IL-6 and TNF-a expression and apoptosis in monocytes (Liao
et al, 2002) indicate that IL-19 may play a part as a keratinocyte-
derived mediator of proin£ammatory signals in psoriatic skin
lesions.
The disappearance of IL-19 and IL-20 mRNA in psoriatic le-
sions following treatment for 28 d with either cyclosporine A or
calcipotriol paralleled or even preceded the clinical and histo-
pathologic improvement of the lesions. Interestingly, the disap-
pearance of IL-19 and IL-20 was almost complete already after
14 d treatment with cyclosporine A, whereas both cytokines were
detectable in the calcipotriol-treated lesions after 14 d. Both
cyclosporine A and calcipotriol led to a disappearance of IL-19
and IL-20 mRNA overexpression in the lesions. This is intri-
guing because it suggests that the two treatments may have
overlapping mechanisms of function. Cyclosporine A is an anti-
in£ammatory agent that primarily acts by blocking of calcineurin
signaling and thereby prevention of IL-2 production in Th1 cells
(Kragballe and Iversen, 1993). The anti-psoriatic e¡ect of calcipo-
triol is thought to be due to induction of di¡erentiation and in-
hibition of proliferation of keratinocytes through stimulation of
the vitamin D3 receptor; however, calcipotriol may in addition
have immunomodulatory functions. Thus, topical calcipotriol
treatment for few days results in reduced IL-8 and increased IL-
10 levels within lesions before any clinical and light microscopic
Figure 6. IL-19 and IL-20 mRNA ex-
pression in psoriatic plaques following
treatment with either cyclosporine A
or calcipotriol. The number of epider-
mal foci with expression of IL-19 (A,C)
and IL-20 (B,D) mRNA was counted in
one in situ hybridized section of each
biopsy (n¼ 80) from all patients included
in the study. The analysis was performed
on sections through the middle of biopsies
from uninvolved skin and psoriatic pla-
ques before (day 0), at day 14 or day 28
after start of treatment with either cyclos-
porine A (A,B) or calcipotriol (C,D).
Figure 7. Correlation of IL-19 and IL-20 mRNA expression with
clinical and histopathologic scores in psoriatic plaques following
treatment with either cyclosporine A or calcipotriol. The diagram
shows the relative values of TSS (’), the histopathologic score ( &), and
the total number of patients with detectable expression of IL-19 mRNA
(E) or IL-20 mRNA ( jjj ) before (day 0), and after 14 d or 28 d of treat-
ment with either cyclosporine A (A) or calcipotriol (B).Values at day 0 are
set to 100%.
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changes can be observed (Kang et al, 1998). Both treatments may
thus be capable of in£uencing the cytokine network in psoriatic
plaques by controlling one or more proin£ammatory factors de-
rived from the activated immune cells primarily located beneath
the epidermal layer and in the papillae.
In a recent study of IL-4-treated patients with severe psoriasis
it was demonstrated that IL-4 improved the clinical scores and
induced Th2 di¡erentiation in CD4þ T cells. Reverse transcrip-
tion^polymerase chain reaction before and after 6 wk of IL-4
treatment showed that IL-19 mRNA expression was downregu-
lated after treatment, whereas no changes in IL-20 and IL-20R
mRNA expression was detected (Ghoreschi et al, 2003). The
downregulation of IL-19 expression following IL-4 therapy indi-
cates that epidermal IL-19 mRNA expression is dependent on
the presence of autoreactive Th1 cells in the lesions. These data
indicate that IL-19 and IL-20 may be di¡erentially regulated in
psoriasis.
It has previously been reported that the proin£ammatory cyto-
kines IL-1b and IL-8 have a similar restricted pattern of expres-
sion in cells in the suprapapillary epidermis of involved skin from
psoriatic patients. IL-8 mRNAwas detected in suprabasal kerati-
nocytes, whereas IL-1b mRNAwas detected in a small number
of papillary cells and in cells in the suprapapillary epidermis. The
IL-1b expressing cells were suggested to be in¢ltrating mononuc-
lear cells (Schmid et al, 1993). The described localization of IL-1b
and IL-8 mRNA in psoriatic skin indicate that they are coex-
pressed with IL-19 and IL-20. If such a colocalization can be es-
tablished in psoriatic plaques it will be interesting to study the
potential interaction between these cytokines.
In conclusion, we have demonstrated a distinct and selective
expression of IL-19 and IL-20 mRNA in suprapapillary keratino-
cytes in chronic psoriatic lesions. Whether IL-19 and IL-20 are
implicated in the pathogenetic mechanisms of psoriasis remains
to be investigated in future studies.
The excellent technical assistance of Jette Mandelbaum, Pia Gottrup Knudsen and
Susanne Primdahl is gratefully acknowledged. Jette Nivaa is acknowledged for excel-
lent secretarial help.
REFERENCES
Blumberg H, Conklin D, XuWF, et al: Interleukin 20. Discovery, receptor identi¢-
cation, and role in epidermal function. Cell 104:9^19, 2001
Caudell EG, Mumm JB, Poindexter N, et al: The protein product of the tumor sup-
pressor gene, melanoma di¡erentiation-associated gene 7, exhibits immunosti-
mulatory activity and is designated IL-24. J Immunol 168:6041^6046, 2002
Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: E⁄-
cacy and safety of in£iximab monotherapy for plaque-type psoriasis: A rando-
mised trial. Lancet 357:1842^1847, 2001
Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC: Cutting edge. STAT
activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of
two types. J Immunol 167:3545^3549, 2001
Ellis CN, Fradin MS, Messana JM, et al: Cyclosporine for plaque-type psoriasis.
Results of a multidose, double-blind trial. N Engl J Med 324:277^284, 1991
Fickenscher H, Hor S, Kupers H, Knappe A,Wittmann S, Sticht H:The interleukin-
10 family of cytokines.Trends Immunol 23:89^96, 2002
Friedrich M, DockeWD, Klein A, Philipp S,Volk HD, SterryW, Asadullah K: Im-
munomodulation by interleukin-10 therapy decreases the incidence of relapse
and prolongs the relapse-free interval in psoriasis. J Invest Dermatol 118:672^677,
2002
Ghoreschi K,Thomas P, Breit S, et al: Interleukin-4 therapy of psoriasis induces Th2
responses and improves human autoimmune disease. Nature Med 9:40^46, 2003
Gruenberg BH, Schoenemeyer A,Weiss B, et al: A novel, soluble homologue of the
human IL-10 receptor with preferential expression in placenta. Genes Immun
2:329^334, 2001
Huang EY, Madireddi MT, Gopalkrishnan RV, et al: Genomic structure, chromoso-
mal localization and expression pro¢le of a novel melanoma di¡erentiation as-
sociated (mda-7) gene with cancer speci¢c growth suppressing and apoptosis
inducing properties. Oncogene 20:7051^7063, 2001
Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB: Subtraction hybridization identi¢es
a novel melanoma di¡erentiation associated gene, mda-7, modulated during
human melanoma di¡erentiation, growth and progression. Oncogene 11:2477^
2486, 1995
Kang S,Yi S, Gri⁄ths CE, et al: Calcipotriene-induced improvement in psoriasis is
associated with reduced interleukin-8 and increased interleukin-10 levels with-
in lesions. Br J Dermatol 138:77^83, 1998
van de Kerkhof PCM: Pathogenesis. In: Textbook of Psoriasis. Edinburgh: Blackwell
Science, 1999; p 79^105
Kotenko SV: The family of IL-10-related cytokines and their receptors: Related, but
to what extent? Cytokine Growth Factor Rev 13:223^240, 2002
Kragballe K, Iversen L: CalcipotriolA new topical antipsoriatic. Dermatol Clin
11:137^141, 1993
LiaoYC, LiangWG, Chen FW, Hsu JH,Yang JJ, Chang MS: IL-19 induces produc-
tion of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha.
J Immunol 169:4288^4297, 2002
Nickolo¡ BJ, Wrone-Smith T: Injection of pre-psoriatic skin with CD4þ T cells
induces psoriasis. AmJ Pathol 155:145^158, 1999
Novak JP, Xu WF, Brender T, et al: Interleukins 19, 20, and 24 signal through two
distinct receptor complexesDi¡erences in receptor^ligand interactions med-
iate unique biological functions. J Biol Chem 277:47517^47523, 2002
Reich K, Garbe C, Blaschke V, et al: Response of psoriasis to interleukin-10 is asso-
ciated with suppression of cutaneous type 1 in£ammation, downregulation of
the epidermal interleukin-8/CXCR2 pathway and normalization of keratino-
cyte maturation. J Invest Dermatol 116:319^329, 2001
Schaefer G, Venkataraman C, Schindler U: Cutting edge. FISP (IL-4-induced se-
creted protein), a novel cytokine-like molecule secreted byTh2 cells. J Immunol
166:5859^5863, 2001
Schmid P, Cox D, McMaster GK, Itin P: In situ hybridization analysis of cytokine,
proto-oncogene and tumour suppressor gene expression in psoriasis. Arch Der-
matol Res 285:334^340, 1993
Soo C, ShawWW, Freymiller E, et al: Cutaneous rat wounds express c49a, a novel
gene with homology to the human melanoma di¡erentiation associated gene,
mda-7. J Cell Biochem 74:1^10, 1999
TrepicchioWL, Ozawa M,Walters IB, et al: Interleukin-11 therapy selectively down-
regulates type I cytokine proin£ammatory pathways in psoriasis lesions. J Clin
Invest 104:1527^1537, 1999
Wang M,Tan ZJ, Zhang R, Kotenko SV, Liang P: Interleukin 24 (MDA-7/MOB-5)
signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/
IL-20R2. J Biol Chem 277:7341^7347, 2002
IL-19, 20 AND 24 EXPRESSION IN PSORIATIC PLAQUES 1311VOL. 121, NO. 6 DECEMBER 2003
